NCT06758700RecruitingPhase 2
Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
Phase II Clinical Study to Evaluate the Efficacy and Safety of Teniposide as a Post-Line Therapy for c-Myc-Driven Extensive-Stage Small Cell Lung Cancer
Source: ClinicalTrials.gov · Last updated 5 Dec 2025
Brief summary (registry, in English)
The study is being conducted to investigate the efficacy and safety of teniposide in patients with extensive-stage small cell lung cancer who have failed standard treatment and with high expression of the c-Myc-driven FBXW2/MYC gene. Based on the results, the study will explore the correlation between the expression of FBXW2/MYC and the efficacy of teniposide.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- First submitted
- 26 Dec 2024
- Start date
- 7 Feb 2025
- Primary completion date
- 30 Jun 2026
- Lead sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Diseases
- Lung cancer
- NCT number
- NCT06758700
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 15
- From 7 Feb 2025 to the primary completion date, 30 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Other severe and persistent diseases or organ system dysfunction;
Other
- No measurable lesions
- Women planning pregnancy or men planning family planning;
- Women who are pregnant or breastfeeding;
- Those who cannot follow the research protocol provided by the investigator.
Who the study is looking for
- extensive stage small cell lung cancer
- Progression after receiving at least one chemotherapy drug treatment in the past;
- ECOG score 0-1
- c-Myc-driven
- Expected survival period ≥3 months
- Age: 18-75 years old;
- The informed consent form complies with the ICH-GCP principles.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghai Pulmonary Hospital, Shanghai. China Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.